Global Pertussis Vaccines Market

Pertussis Vaccines Comprehensive Study by Type (Whole-Cell Vaccines, A-Cellular Vaccines), Application (Pediatrics, Adults), Vaccine Type (DTaP (Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quaracel), Tdap (Boostrix and Adacel)), End User (Hospitals, Clinics, Vaccine Centers) Players and Region - Global Market Outlook to 2027

Pertussis Vaccines Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 1.6%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Pertussis Vaccines Market Scope?
The pertussis vaccine is used against whooping cough. This vaccine is only available in combination with other vaccines. The pertussis vaccination is recommended for all children, babies, adolescents, and pregnant women. Diphtheria, tetanus, and pertussis (DTaP) vaccines are given to children under the age of seven, while tetanus, diphtheria, and pertussis (Tdap) vaccines are given to older children and adults. Childhood vaccination is one of the safest and cheapest ways to have a pertussis-free environment. The World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) recommend that all children should be routinely vaccinated against pertussis. According to the WHO, around 86% of infants worldwide received three doses of diphtheria-tetanus-pertussis (DTP3) vaccine in 2015 to protect them from infectious diseases. In 2015, DTwP vaccine sourcing through UNICEF had reached 5.8 million doses for 18 countries and territories, four of which such as Egypt, Morocco, Uzbekistan and Zimbabwe accounted for more than 80% of UNICEF's total sourcing. Factors such as the high birth rate, the increase in the geriatric population, government initiatives, and the increase in the adoption of pertussis vaccinations, and the government insurance and reimbursement scenario are thereby expected to drive the pertussis vaccine market globally.

Pertussis Vaccines Market Dynamics:
AttributesDetails
Growth Drivers
  • High Birth Rate
  • Increase in Number of Geriatric Population
  • Rising Government Initiatives
  • Growth in Adoption of Pertussis Vaccination
Influencing Trends
  • Growth in Awareness among People
  • Government Insurance and Reimbursement Scenario
Restraints
  • High Cost of Vaccine Development
  • Vaccine Injuries and Adverse Effects of the Vaccine
Road Blocks / Challenges
  • Inadequate Access to Vaccines in Under Developed Countries
Gaps & Opportunities
  • Rise in Number of Government and Private Health Care Insurance Coverage
  • Increase in Health Care Expenditure


The Pertussis Vaccines market study is being classified by Type (Whole-Cell Vaccines and A-Cellular Vaccines), by Application and major geographies with country level break-up. According to AMA, the Global Pertussis Vaccines market is expected to see growth rate of 1.6% and may see market size of USD5.5 Billion by 2027.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analysts at AMA predicts that Players from European and United States will contribute to the maximum growth of Global Pertussis Vaccines market throughout the predicted period.

Sanofi Pasteur (France), GlaxoSmithKline (United Kingdom), Protein Sciences Corporation (United States), Novartis AG (Switzerland), Seqirus (United Kingdom), Merck Sharp & Dohme Corp. (United States), Astellas Pharma US, Inc. (United States), Mitsubishi Tanabe Pharma (Japan), Wuhan Institute of Biological Products (China), Walvax Biotechnology Co (China) and Beijing Minhai Biotechnology Co (China) are some of the key players profiled in the study.

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Pertussis Vaccines market by Type, Application and Region.

On the basis of geography, the market of Pertussis Vaccines has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Influencers and their Development Strategies
In, February 2020 A Chinese biotech had partnered with GSK for boosting its coronavirus vaccine development so as to stop the infection from the coronavirus.
In February 2020, Sanofi Pasteur had developed the COVID-19 vaccine with the US government. The global business unit of French drugmaker Sanofi had joined forces with a US government department to develop a novel COVID-19 coronavirus vaccine. and In November 2019, Sanofi’s high-dose quadrivalent flu vaccine was approved for older people.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Manufacturers of Pertussis Vaccine, Suppliers and Distributors of Pertussis Vaccine, Venture Capitalists and Private Equity Firms and End-Use Industry

Pertussis Vaccines Market Study: Important Years
AttributesDetails
Study Period2017-2027
Base Year2021
Forecast Period2022-2027
Historical Period2017-2021
UnitValue (USD Billion)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • Whole-Cell Vaccines
  • A-Cellular Vaccines
By Application
  • Pediatrics
  • Adults
By Vaccine Type
  • DTaP [Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quaracel]
  • Tdap [Boostrix and Adacel]

By End User
  • Hospitals
  • Clinics
  • Vaccine Centers

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High Birth Rate
      • 3.2.2. Increase in Number of Geriatric Population
      • 3.2.3. Rising Government Initiatives
      • 3.2.4. Growth in Adoption of Pertussis Vaccination
    • 3.3. Market Challenges
      • 3.3.1. Inadequate Access to Vaccines in Under Developed Countries
    • 3.4. Market Trends
      • 3.4.1. Growth in Awareness among People
      • 3.4.2. Government Insurance and Reimbursement Scenario
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pertussis Vaccines, by Type, Application, Vaccine Type, End User and Region (value, volume and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Pertussis Vaccines (Value)
      • 5.2.1. Global Pertussis Vaccines by: Type (Value)
        • 5.2.1.1. Whole-Cell Vaccines
        • 5.2.1.2. A-Cellular Vaccines
      • 5.2.2. Global Pertussis Vaccines by: Application (Value)
        • 5.2.2.1. Pediatrics
        • 5.2.2.2. Adults
      • 5.2.3. Global Pertussis Vaccines by: Vaccine Type (Value)
        • 5.2.3.1. DTaP [Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quaracel]
        • 5.2.3.2. Tdap [Boostrix and Adacel]
      • 5.2.4. Global Pertussis Vaccines by: End User (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Clinics
        • 5.2.4.3. Vaccine Centers
      • 5.2.5. Global Pertussis Vaccines Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Pertussis Vaccines (Volume)
      • 5.3.1. Global Pertussis Vaccines by: Type (Volume)
        • 5.3.1.1. Whole-Cell Vaccines
        • 5.3.1.2. A-Cellular Vaccines
      • 5.3.2. Global Pertussis Vaccines by: Application (Volume)
        • 5.3.2.1. Pediatrics
        • 5.3.2.2. Adults
      • 5.3.3. Global Pertussis Vaccines by: Vaccine Type (Volume)
        • 5.3.3.1. DTaP [Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quaracel]
        • 5.3.3.2. Tdap [Boostrix and Adacel]
      • 5.3.4. Global Pertussis Vaccines by: End User (Volume)
        • 5.3.4.1. Hospitals
        • 5.3.4.2. Clinics
        • 5.3.4.3. Vaccine Centers
      • 5.3.5. Global Pertussis Vaccines Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Pertussis Vaccines (Price)
      • 5.4.1. Global Pertussis Vaccines by: Type (Price)
  • 6. Pertussis Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sanofi Pasteur (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Protein Sciences Corporation (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Seqirus (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck Sharp & Dohme Corp. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Astellas Pharma US, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Mitsubishi Tanabe Pharma (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Wuhan Institute of Biological Products (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Walvax Biotechnology Co (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Beijing Minhai Biotechnology Co (China)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Pertussis Vaccines Sale, by Type, Application, Vaccine Type, End User and Region (value, volume and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Pertussis Vaccines (Value)
      • 7.2.1. Global Pertussis Vaccines by: Type (Value)
        • 7.2.1.1. Whole-Cell Vaccines
        • 7.2.1.2. A-Cellular Vaccines
      • 7.2.2. Global Pertussis Vaccines by: Application (Value)
        • 7.2.2.1. Pediatrics
        • 7.2.2.2. Adults
      • 7.2.3. Global Pertussis Vaccines by: Vaccine Type (Value)
        • 7.2.3.1. DTaP [Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quaracel]
        • 7.2.3.2. Tdap [Boostrix and Adacel]
      • 7.2.4. Global Pertussis Vaccines by: End User (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Clinics
        • 7.2.4.3. Vaccine Centers
      • 7.2.5. Global Pertussis Vaccines Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Pertussis Vaccines (Volume)
      • 7.3.1. Global Pertussis Vaccines by: Type (Volume)
        • 7.3.1.1. Whole-Cell Vaccines
        • 7.3.1.2. A-Cellular Vaccines
      • 7.3.2. Global Pertussis Vaccines by: Application (Volume)
        • 7.3.2.1. Pediatrics
        • 7.3.2.2. Adults
      • 7.3.3. Global Pertussis Vaccines by: Vaccine Type (Volume)
        • 7.3.3.1. DTaP [Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quaracel]
        • 7.3.3.2. Tdap [Boostrix and Adacel]
      • 7.3.4. Global Pertussis Vaccines by: End User (Volume)
        • 7.3.4.1. Hospitals
        • 7.3.4.2. Clinics
        • 7.3.4.3. Vaccine Centers
      • 7.3.5. Global Pertussis Vaccines Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Pertussis Vaccines (Price)
      • 7.4.1. Global Pertussis Vaccines by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pertussis Vaccines: by Type(USD Billion)
  • Table 2. Pertussis Vaccines Whole-Cell Vaccines , by Region USD Billion (2016-2021)
  • Table 3. Pertussis Vaccines A-Cellular Vaccines , by Region USD Billion (2016-2021)
  • Table 4. Pertussis Vaccines: by Application(USD Billion)
  • Table 5. Pertussis Vaccines Pediatrics , by Region USD Billion (2016-2021)
  • Table 6. Pertussis Vaccines Adults , by Region USD Billion (2016-2021)
  • Table 7. Pertussis Vaccines: by Vaccine Type(USD Billion)
  • Table 8. Pertussis Vaccines DTaP [Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quaracel] , by Region USD Billion (2016-2021)
  • Table 9. Pertussis Vaccines Tdap [Boostrix and Adacel] , by Region USD Billion (2016-2021)
  • Table 10. Pertussis Vaccines: by End User(USD Billion)
  • Table 11. Pertussis Vaccines Hospitals , by Region USD Billion (2016-2021)
  • Table 12. Pertussis Vaccines Clinics , by Region USD Billion (2016-2021)
  • Table 13. Pertussis Vaccines Vaccine Centers , by Region USD Billion (2016-2021)
  • Table 14. South America Pertussis Vaccines, by Country USD Billion (2016-2021)
  • Table 15. South America Pertussis Vaccines, by Type USD Billion (2016-2021)
  • Table 16. South America Pertussis Vaccines, by Application USD Billion (2016-2021)
  • Table 17. South America Pertussis Vaccines, by Vaccine Type USD Billion (2016-2021)
  • Table 18. South America Pertussis Vaccines, by End User USD Billion (2016-2021)
  • Table 19. Brazil Pertussis Vaccines, by Type USD Billion (2016-2021)
  • Table 20. Brazil Pertussis Vaccines, by Application USD Billion (2016-2021)
  • Table 21. Brazil Pertussis Vaccines, by Vaccine Type USD Billion (2016-2021)
  • Table 22. Brazil Pertussis Vaccines, by End User USD Billion (2016-2021)
  • Table 23. Argentina Pertussis Vaccines, by Type USD Billion (2016-2021)
  • Table 24. Argentina Pertussis Vaccines, by Application USD Billion (2016-2021)
  • Table 25. Argentina Pertussis Vaccines, by Vaccine Type USD Billion (2016-2021)
  • Table 26. Argentina Pertussis Vaccines, by End User USD Billion (2016-2021)
  • Table 27. Rest of South America Pertussis Vaccines, by Type USD Billion (2016-2021)
  • Table 28. Rest of South America Pertussis Vaccines, by Application USD Billion (2016-2021)
  • Table 29. Rest of South America Pertussis Vaccines, by Vaccine Type USD Billion (2016-2021)
  • Table 30. Rest of South America Pertussis Vaccines, by End User USD Billion (2016-2021)
  • Table 31. Asia Pacific Pertussis Vaccines, by Country USD Billion (2016-2021)
  • Table 32. Asia Pacific Pertussis Vaccines, by Type USD Billion (2016-2021)
  • Table 33. Asia Pacific Pertussis Vaccines, by Application USD Billion (2016-2021)
  • Table 34. Asia Pacific Pertussis Vaccines, by Vaccine Type USD Billion (2016-2021)
  • Table 35. Asia Pacific Pertussis Vaccines, by End User USD Billion (2016-2021)
  • Table 36. China Pertussis Vaccines, by Type USD Billion (2016-2021)
  • Table 37. China Pertussis Vaccines, by Application USD Billion (2016-2021)
  • Table 38. China Pertussis Vaccines, by Vaccine Type USD Billion (2016-2021)
  • Table 39. China Pertussis Vaccines, by End User USD Billion (2016-2021)
  • Table 40. Japan Pertussis Vaccines, by Type USD Billion (2016-2021)
  • Table 41. Japan Pertussis Vaccines, by Application USD Billion (2016-2021)
  • Table 42. Japan Pertussis Vaccines, by Vaccine Type USD Billion (2016-2021)
  • Table 43. Japan Pertussis Vaccines, by End User USD Billion (2016-2021)
  • Table 44. India Pertussis Vaccines, by Type USD Billion (2016-2021)
  • Table 45. India Pertussis Vaccines, by Application USD Billion (2016-2021)
  • Table 46. India Pertussis Vaccines, by Vaccine Type USD Billion (2016-2021)
  • Table 47. India Pertussis Vaccines, by End User USD Billion (2016-2021)
  • Table 48. South Korea Pertussis Vaccines, by Type USD Billion (2016-2021)
  • Table 49. South Korea Pertussis Vaccines, by Application USD Billion (2016-2021)
  • Table 50. South Korea Pertussis Vaccines, by Vaccine Type USD Billion (2016-2021)
  • Table 51. South Korea Pertussis Vaccines, by End User USD Billion (2016-2021)
  • Table 52. Taiwan Pertussis Vaccines, by Type USD Billion (2016-2021)
  • Table 53. Taiwan Pertussis Vaccines, by Application USD Billion (2016-2021)
  • Table 54. Taiwan Pertussis Vaccines, by Vaccine Type USD Billion (2016-2021)
  • Table 55. Taiwan Pertussis Vaccines, by End User USD Billion (2016-2021)
  • Table 56. Australia Pertussis Vaccines, by Type USD Billion (2016-2021)
  • Table 57. Australia Pertussis Vaccines, by Application USD Billion (2016-2021)
  • Table 58. Australia Pertussis Vaccines, by Vaccine Type USD Billion (2016-2021)
  • Table 59. Australia Pertussis Vaccines, by End User USD Billion (2016-2021)
  • Table 60. Rest of Asia-Pacific Pertussis Vaccines, by Type USD Billion (2016-2021)
  • Table 61. Rest of Asia-Pacific Pertussis Vaccines, by Application USD Billion (2016-2021)
  • Table 62. Rest of Asia-Pacific Pertussis Vaccines, by Vaccine Type USD Billion (2016-2021)
  • Table 63. Rest of Asia-Pacific Pertussis Vaccines, by End User USD Billion (2016-2021)
  • Table 64. Europe Pertussis Vaccines, by Country USD Billion (2016-2021)
  • Table 65. Europe Pertussis Vaccines, by Type USD Billion (2016-2021)
  • Table 66. Europe Pertussis Vaccines, by Application USD Billion (2016-2021)
  • Table 67. Europe Pertussis Vaccines, by Vaccine Type USD Billion (2016-2021)
  • Table 68. Europe Pertussis Vaccines, by End User USD Billion (2016-2021)
  • Table 69. Germany Pertussis Vaccines, by Type USD Billion (2016-2021)
  • Table 70. Germany Pertussis Vaccines, by Application USD Billion (2016-2021)
  • Table 71. Germany Pertussis Vaccines, by Vaccine Type USD Billion (2016-2021)
  • Table 72. Germany Pertussis Vaccines, by End User USD Billion (2016-2021)
  • Table 73. France Pertussis Vaccines, by Type USD Billion (2016-2021)
  • Table 74. France Pertussis Vaccines, by Application USD Billion (2016-2021)
  • Table 75. France Pertussis Vaccines, by Vaccine Type USD Billion (2016-2021)
  • Table 76. France Pertussis Vaccines, by End User USD Billion (2016-2021)
  • Table 77. Italy Pertussis Vaccines, by Type USD Billion (2016-2021)
  • Table 78. Italy Pertussis Vaccines, by Application USD Billion (2016-2021)
  • Table 79. Italy Pertussis Vaccines, by Vaccine Type USD Billion (2016-2021)
  • Table 80. Italy Pertussis Vaccines, by End User USD Billion (2016-2021)
  • Table 81. United Kingdom Pertussis Vaccines, by Type USD Billion (2016-2021)
  • Table 82. United Kingdom Pertussis Vaccines, by Application USD Billion (2016-2021)
  • Table 83. United Kingdom Pertussis Vaccines, by Vaccine Type USD Billion (2016-2021)
  • Table 84. United Kingdom Pertussis Vaccines, by End User USD Billion (2016-2021)
  • Table 85. Netherlands Pertussis Vaccines, by Type USD Billion (2016-2021)
  • Table 86. Netherlands Pertussis Vaccines, by Application USD Billion (2016-2021)
  • Table 87. Netherlands Pertussis Vaccines, by Vaccine Type USD Billion (2016-2021)
  • Table 88. Netherlands Pertussis Vaccines, by End User USD Billion (2016-2021)
  • Table 89. Rest of Europe Pertussis Vaccines, by Type USD Billion (2016-2021)
  • Table 90. Rest of Europe Pertussis Vaccines, by Application USD Billion (2016-2021)
  • Table 91. Rest of Europe Pertussis Vaccines, by Vaccine Type USD Billion (2016-2021)
  • Table 92. Rest of Europe Pertussis Vaccines, by End User USD Billion (2016-2021)
  • Table 93. MEA Pertussis Vaccines, by Country USD Billion (2016-2021)
  • Table 94. MEA Pertussis Vaccines, by Type USD Billion (2016-2021)
  • Table 95. MEA Pertussis Vaccines, by Application USD Billion (2016-2021)
  • Table 96. MEA Pertussis Vaccines, by Vaccine Type USD Billion (2016-2021)
  • Table 97. MEA Pertussis Vaccines, by End User USD Billion (2016-2021)
  • Table 98. Middle East Pertussis Vaccines, by Type USD Billion (2016-2021)
  • Table 99. Middle East Pertussis Vaccines, by Application USD Billion (2016-2021)
  • Table 100. Middle East Pertussis Vaccines, by Vaccine Type USD Billion (2016-2021)
  • Table 101. Middle East Pertussis Vaccines, by End User USD Billion (2016-2021)
  • Table 102. Africa Pertussis Vaccines, by Type USD Billion (2016-2021)
  • Table 103. Africa Pertussis Vaccines, by Application USD Billion (2016-2021)
  • Table 104. Africa Pertussis Vaccines, by Vaccine Type USD Billion (2016-2021)
  • Table 105. Africa Pertussis Vaccines, by End User USD Billion (2016-2021)
  • Table 106. North America Pertussis Vaccines, by Country USD Billion (2016-2021)
  • Table 107. North America Pertussis Vaccines, by Type USD Billion (2016-2021)
  • Table 108. North America Pertussis Vaccines, by Application USD Billion (2016-2021)
  • Table 109. North America Pertussis Vaccines, by Vaccine Type USD Billion (2016-2021)
  • Table 110. North America Pertussis Vaccines, by End User USD Billion (2016-2021)
  • Table 111. United States Pertussis Vaccines, by Type USD Billion (2016-2021)
  • Table 112. United States Pertussis Vaccines, by Application USD Billion (2016-2021)
  • Table 113. United States Pertussis Vaccines, by Vaccine Type USD Billion (2016-2021)
  • Table 114. United States Pertussis Vaccines, by End User USD Billion (2016-2021)
  • Table 115. Canada Pertussis Vaccines, by Type USD Billion (2016-2021)
  • Table 116. Canada Pertussis Vaccines, by Application USD Billion (2016-2021)
  • Table 117. Canada Pertussis Vaccines, by Vaccine Type USD Billion (2016-2021)
  • Table 118. Canada Pertussis Vaccines, by End User USD Billion (2016-2021)
  • Table 119. Mexico Pertussis Vaccines, by Type USD Billion (2016-2021)
  • Table 120. Mexico Pertussis Vaccines, by Application USD Billion (2016-2021)
  • Table 121. Mexico Pertussis Vaccines, by Vaccine Type USD Billion (2016-2021)
  • Table 122. Mexico Pertussis Vaccines, by End User USD Billion (2016-2021)
  • Table 123. Pertussis Vaccines Sales: by Type(K Units)
  • Table 124. Pertussis Vaccines Sales Whole-Cell Vaccines , by Region K Units (2016-2021)
  • Table 125. Pertussis Vaccines Sales A-Cellular Vaccines , by Region K Units (2016-2021)
  • Table 126. Pertussis Vaccines Sales: by Application(K Units)
  • Table 127. Pertussis Vaccines Sales Pediatrics , by Region K Units (2016-2021)
  • Table 128. Pertussis Vaccines Sales Adults , by Region K Units (2016-2021)
  • Table 129. Pertussis Vaccines Sales: by Vaccine Type(K Units)
  • Table 130. Pertussis Vaccines Sales DTaP [Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quaracel] , by Region K Units (2016-2021)
  • Table 131. Pertussis Vaccines Sales Tdap [Boostrix and Adacel] , by Region K Units (2016-2021)
  • Table 132. Pertussis Vaccines Sales: by End User(K Units)
  • Table 133. Pertussis Vaccines Sales Hospitals , by Region K Units (2016-2021)
  • Table 134. Pertussis Vaccines Sales Clinics , by Region K Units (2016-2021)
  • Table 135. Pertussis Vaccines Sales Vaccine Centers , by Region K Units (2016-2021)
  • Table 136. South America Pertussis Vaccines Sales, by Country K Units (2016-2021)
  • Table 137. South America Pertussis Vaccines Sales, by Type K Units (2016-2021)
  • Table 138. South America Pertussis Vaccines Sales, by Application K Units (2016-2021)
  • Table 139. South America Pertussis Vaccines Sales, by Vaccine Type K Units (2016-2021)
  • Table 140. South America Pertussis Vaccines Sales, by End User K Units (2016-2021)
  • Table 141. Brazil Pertussis Vaccines Sales, by Type K Units (2016-2021)
  • Table 142. Brazil Pertussis Vaccines Sales, by Application K Units (2016-2021)
  • Table 143. Brazil Pertussis Vaccines Sales, by Vaccine Type K Units (2016-2021)
  • Table 144. Brazil Pertussis Vaccines Sales, by End User K Units (2016-2021)
  • Table 145. Argentina Pertussis Vaccines Sales, by Type K Units (2016-2021)
  • Table 146. Argentina Pertussis Vaccines Sales, by Application K Units (2016-2021)
  • Table 147. Argentina Pertussis Vaccines Sales, by Vaccine Type K Units (2016-2021)
  • Table 148. Argentina Pertussis Vaccines Sales, by End User K Units (2016-2021)
  • Table 149. Rest of South America Pertussis Vaccines Sales, by Type K Units (2016-2021)
  • Table 150. Rest of South America Pertussis Vaccines Sales, by Application K Units (2016-2021)
  • Table 151. Rest of South America Pertussis Vaccines Sales, by Vaccine Type K Units (2016-2021)
  • Table 152. Rest of South America Pertussis Vaccines Sales, by End User K Units (2016-2021)
  • Table 153. Asia Pacific Pertussis Vaccines Sales, by Country K Units (2016-2021)
  • Table 154. Asia Pacific Pertussis Vaccines Sales, by Type K Units (2016-2021)
  • Table 155. Asia Pacific Pertussis Vaccines Sales, by Application K Units (2016-2021)
  • Table 156. Asia Pacific Pertussis Vaccines Sales, by Vaccine Type K Units (2016-2021)
  • Table 157. Asia Pacific Pertussis Vaccines Sales, by End User K Units (2016-2021)
  • Table 158. China Pertussis Vaccines Sales, by Type K Units (2016-2021)
  • Table 159. China Pertussis Vaccines Sales, by Application K Units (2016-2021)
  • Table 160. China Pertussis Vaccines Sales, by Vaccine Type K Units (2016-2021)
  • Table 161. China Pertussis Vaccines Sales, by End User K Units (2016-2021)
  • Table 162. Japan Pertussis Vaccines Sales, by Type K Units (2016-2021)
  • Table 163. Japan Pertussis Vaccines Sales, by Application K Units (2016-2021)
  • Table 164. Japan Pertussis Vaccines Sales, by Vaccine Type K Units (2016-2021)
  • Table 165. Japan Pertussis Vaccines Sales, by End User K Units (2016-2021)
  • Table 166. India Pertussis Vaccines Sales, by Type K Units (2016-2021)
  • Table 167. India Pertussis Vaccines Sales, by Application K Units (2016-2021)
  • Table 168. India Pertussis Vaccines Sales, by Vaccine Type K Units (2016-2021)
  • Table 169. India Pertussis Vaccines Sales, by End User K Units (2016-2021)
  • Table 170. South Korea Pertussis Vaccines Sales, by Type K Units (2016-2021)
  • Table 171. South Korea Pertussis Vaccines Sales, by Application K Units (2016-2021)
  • Table 172. South Korea Pertussis Vaccines Sales, by Vaccine Type K Units (2016-2021)
  • Table 173. South Korea Pertussis Vaccines Sales, by End User K Units (2016-2021)
  • Table 174. Taiwan Pertussis Vaccines Sales, by Type K Units (2016-2021)
  • Table 175. Taiwan Pertussis Vaccines Sales, by Application K Units (2016-2021)
  • Table 176. Taiwan Pertussis Vaccines Sales, by Vaccine Type K Units (2016-2021)
  • Table 177. Taiwan Pertussis Vaccines Sales, by End User K Units (2016-2021)
  • Table 178. Australia Pertussis Vaccines Sales, by Type K Units (2016-2021)
  • Table 179. Australia Pertussis Vaccines Sales, by Application K Units (2016-2021)
  • Table 180. Australia Pertussis Vaccines Sales, by Vaccine Type K Units (2016-2021)
  • Table 181. Australia Pertussis Vaccines Sales, by End User K Units (2016-2021)
  • Table 182. Rest of Asia-Pacific Pertussis Vaccines Sales, by Type K Units (2016-2021)
  • Table 183. Rest of Asia-Pacific Pertussis Vaccines Sales, by Application K Units (2016-2021)
  • Table 184. Rest of Asia-Pacific Pertussis Vaccines Sales, by Vaccine Type K Units (2016-2021)
  • Table 185. Rest of Asia-Pacific Pertussis Vaccines Sales, by End User K Units (2016-2021)
  • Table 186. Europe Pertussis Vaccines Sales, by Country K Units (2016-2021)
  • Table 187. Europe Pertussis Vaccines Sales, by Type K Units (2016-2021)
  • Table 188. Europe Pertussis Vaccines Sales, by Application K Units (2016-2021)
  • Table 189. Europe Pertussis Vaccines Sales, by Vaccine Type K Units (2016-2021)
  • Table 190. Europe Pertussis Vaccines Sales, by End User K Units (2016-2021)
  • Table 191. Germany Pertussis Vaccines Sales, by Type K Units (2016-2021)
  • Table 192. Germany Pertussis Vaccines Sales, by Application K Units (2016-2021)
  • Table 193. Germany Pertussis Vaccines Sales, by Vaccine Type K Units (2016-2021)
  • Table 194. Germany Pertussis Vaccines Sales, by End User K Units (2016-2021)
  • Table 195. France Pertussis Vaccines Sales, by Type K Units (2016-2021)
  • Table 196. France Pertussis Vaccines Sales, by Application K Units (2016-2021)
  • Table 197. France Pertussis Vaccines Sales, by Vaccine Type K Units (2016-2021)
  • Table 198. France Pertussis Vaccines Sales, by End User K Units (2016-2021)
  • Table 199. Italy Pertussis Vaccines Sales, by Type K Units (2016-2021)
  • Table 200. Italy Pertussis Vaccines Sales, by Application K Units (2016-2021)
  • Table 201. Italy Pertussis Vaccines Sales, by Vaccine Type K Units (2016-2021)
  • Table 202. Italy Pertussis Vaccines Sales, by End User K Units (2016-2021)
  • Table 203. United Kingdom Pertussis Vaccines Sales, by Type K Units (2016-2021)
  • Table 204. United Kingdom Pertussis Vaccines Sales, by Application K Units (2016-2021)
  • Table 205. United Kingdom Pertussis Vaccines Sales, by Vaccine Type K Units (2016-2021)
  • Table 206. United Kingdom Pertussis Vaccines Sales, by End User K Units (2016-2021)
  • Table 207. Netherlands Pertussis Vaccines Sales, by Type K Units (2016-2021)
  • Table 208. Netherlands Pertussis Vaccines Sales, by Application K Units (2016-2021)
  • Table 209. Netherlands Pertussis Vaccines Sales, by Vaccine Type K Units (2016-2021)
  • Table 210. Netherlands Pertussis Vaccines Sales, by End User K Units (2016-2021)
  • Table 211. Rest of Europe Pertussis Vaccines Sales, by Type K Units (2016-2021)
  • Table 212. Rest of Europe Pertussis Vaccines Sales, by Application K Units (2016-2021)
  • Table 213. Rest of Europe Pertussis Vaccines Sales, by Vaccine Type K Units (2016-2021)
  • Table 214. Rest of Europe Pertussis Vaccines Sales, by End User K Units (2016-2021)
  • Table 215. MEA Pertussis Vaccines Sales, by Country K Units (2016-2021)
  • Table 216. MEA Pertussis Vaccines Sales, by Type K Units (2016-2021)
  • Table 217. MEA Pertussis Vaccines Sales, by Application K Units (2016-2021)
  • Table 218. MEA Pertussis Vaccines Sales, by Vaccine Type K Units (2016-2021)
  • Table 219. MEA Pertussis Vaccines Sales, by End User K Units (2016-2021)
  • Table 220. Middle East Pertussis Vaccines Sales, by Type K Units (2016-2021)
  • Table 221. Middle East Pertussis Vaccines Sales, by Application K Units (2016-2021)
  • Table 222. Middle East Pertussis Vaccines Sales, by Vaccine Type K Units (2016-2021)
  • Table 223. Middle East Pertussis Vaccines Sales, by End User K Units (2016-2021)
  • Table 224. Africa Pertussis Vaccines Sales, by Type K Units (2016-2021)
  • Table 225. Africa Pertussis Vaccines Sales, by Application K Units (2016-2021)
  • Table 226. Africa Pertussis Vaccines Sales, by Vaccine Type K Units (2016-2021)
  • Table 227. Africa Pertussis Vaccines Sales, by End User K Units (2016-2021)
  • Table 228. North America Pertussis Vaccines Sales, by Country K Units (2016-2021)
  • Table 229. North America Pertussis Vaccines Sales, by Type K Units (2016-2021)
  • Table 230. North America Pertussis Vaccines Sales, by Application K Units (2016-2021)
  • Table 231. North America Pertussis Vaccines Sales, by Vaccine Type K Units (2016-2021)
  • Table 232. North America Pertussis Vaccines Sales, by End User K Units (2016-2021)
  • Table 233. United States Pertussis Vaccines Sales, by Type K Units (2016-2021)
  • Table 234. United States Pertussis Vaccines Sales, by Application K Units (2016-2021)
  • Table 235. United States Pertussis Vaccines Sales, by Vaccine Type K Units (2016-2021)
  • Table 236. United States Pertussis Vaccines Sales, by End User K Units (2016-2021)
  • Table 237. Canada Pertussis Vaccines Sales, by Type K Units (2016-2021)
  • Table 238. Canada Pertussis Vaccines Sales, by Application K Units (2016-2021)
  • Table 239. Canada Pertussis Vaccines Sales, by Vaccine Type K Units (2016-2021)
  • Table 240. Canada Pertussis Vaccines Sales, by End User K Units (2016-2021)
  • Table 241. Mexico Pertussis Vaccines Sales, by Type K Units (2016-2021)
  • Table 242. Mexico Pertussis Vaccines Sales, by Application K Units (2016-2021)
  • Table 243. Mexico Pertussis Vaccines Sales, by Vaccine Type K Units (2016-2021)
  • Table 244. Mexico Pertussis Vaccines Sales, by End User K Units (2016-2021)
  • Table 245. Pertussis Vaccines: by Type(USD/Units)
  • Table 246. Company Basic Information, Sales Area and Its Competitors
  • Table 247. Company Basic Information, Sales Area and Its Competitors
  • Table 248. Company Basic Information, Sales Area and Its Competitors
  • Table 249. Company Basic Information, Sales Area and Its Competitors
  • Table 250. Company Basic Information, Sales Area and Its Competitors
  • Table 251. Company Basic Information, Sales Area and Its Competitors
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Pertussis Vaccines: by Type(USD Billion)
  • Table 258. Pertussis Vaccines Whole-Cell Vaccines , by Region USD Billion (2022-2027)
  • Table 259. Pertussis Vaccines A-Cellular Vaccines , by Region USD Billion (2022-2027)
  • Table 260. Pertussis Vaccines: by Application(USD Billion)
  • Table 261. Pertussis Vaccines Pediatrics , by Region USD Billion (2022-2027)
  • Table 262. Pertussis Vaccines Adults , by Region USD Billion (2022-2027)
  • Table 263. Pertussis Vaccines: by Vaccine Type(USD Billion)
  • Table 264. Pertussis Vaccines DTaP [Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quaracel] , by Region USD Billion (2022-2027)
  • Table 265. Pertussis Vaccines Tdap [Boostrix and Adacel] , by Region USD Billion (2022-2027)
  • Table 266. Pertussis Vaccines: by End User(USD Billion)
  • Table 267. Pertussis Vaccines Hospitals , by Region USD Billion (2022-2027)
  • Table 268. Pertussis Vaccines Clinics , by Region USD Billion (2022-2027)
  • Table 269. Pertussis Vaccines Vaccine Centers , by Region USD Billion (2022-2027)
  • Table 270. South America Pertussis Vaccines, by Country USD Billion (2022-2027)
  • Table 271. South America Pertussis Vaccines, by Type USD Billion (2022-2027)
  • Table 272. South America Pertussis Vaccines, by Application USD Billion (2022-2027)
  • Table 273. South America Pertussis Vaccines, by Vaccine Type USD Billion (2022-2027)
  • Table 274. South America Pertussis Vaccines, by End User USD Billion (2022-2027)
  • Table 275. Brazil Pertussis Vaccines, by Type USD Billion (2022-2027)
  • Table 276. Brazil Pertussis Vaccines, by Application USD Billion (2022-2027)
  • Table 277. Brazil Pertussis Vaccines, by Vaccine Type USD Billion (2022-2027)
  • Table 278. Brazil Pertussis Vaccines, by End User USD Billion (2022-2027)
  • Table 279. Argentina Pertussis Vaccines, by Type USD Billion (2022-2027)
  • Table 280. Argentina Pertussis Vaccines, by Application USD Billion (2022-2027)
  • Table 281. Argentina Pertussis Vaccines, by Vaccine Type USD Billion (2022-2027)
  • Table 282. Argentina Pertussis Vaccines, by End User USD Billion (2022-2027)
  • Table 283. Rest of South America Pertussis Vaccines, by Type USD Billion (2022-2027)
  • Table 284. Rest of South America Pertussis Vaccines, by Application USD Billion (2022-2027)
  • Table 285. Rest of South America Pertussis Vaccines, by Vaccine Type USD Billion (2022-2027)
  • Table 286. Rest of South America Pertussis Vaccines, by End User USD Billion (2022-2027)
  • Table 287. Asia Pacific Pertussis Vaccines, by Country USD Billion (2022-2027)
  • Table 288. Asia Pacific Pertussis Vaccines, by Type USD Billion (2022-2027)
  • Table 289. Asia Pacific Pertussis Vaccines, by Application USD Billion (2022-2027)
  • Table 290. Asia Pacific Pertussis Vaccines, by Vaccine Type USD Billion (2022-2027)
  • Table 291. Asia Pacific Pertussis Vaccines, by End User USD Billion (2022-2027)
  • Table 292. China Pertussis Vaccines, by Type USD Billion (2022-2027)
  • Table 293. China Pertussis Vaccines, by Application USD Billion (2022-2027)
  • Table 294. China Pertussis Vaccines, by Vaccine Type USD Billion (2022-2027)
  • Table 295. China Pertussis Vaccines, by End User USD Billion (2022-2027)
  • Table 296. Japan Pertussis Vaccines, by Type USD Billion (2022-2027)
  • Table 297. Japan Pertussis Vaccines, by Application USD Billion (2022-2027)
  • Table 298. Japan Pertussis Vaccines, by Vaccine Type USD Billion (2022-2027)
  • Table 299. Japan Pertussis Vaccines, by End User USD Billion (2022-2027)
  • Table 300. India Pertussis Vaccines, by Type USD Billion (2022-2027)
  • Table 301. India Pertussis Vaccines, by Application USD Billion (2022-2027)
  • Table 302. India Pertussis Vaccines, by Vaccine Type USD Billion (2022-2027)
  • Table 303. India Pertussis Vaccines, by End User USD Billion (2022-2027)
  • Table 304. South Korea Pertussis Vaccines, by Type USD Billion (2022-2027)
  • Table 305. South Korea Pertussis Vaccines, by Application USD Billion (2022-2027)
  • Table 306. South Korea Pertussis Vaccines, by Vaccine Type USD Billion (2022-2027)
  • Table 307. South Korea Pertussis Vaccines, by End User USD Billion (2022-2027)
  • Table 308. Taiwan Pertussis Vaccines, by Type USD Billion (2022-2027)
  • Table 309. Taiwan Pertussis Vaccines, by Application USD Billion (2022-2027)
  • Table 310. Taiwan Pertussis Vaccines, by Vaccine Type USD Billion (2022-2027)
  • Table 311. Taiwan Pertussis Vaccines, by End User USD Billion (2022-2027)
  • Table 312. Australia Pertussis Vaccines, by Type USD Billion (2022-2027)
  • Table 313. Australia Pertussis Vaccines, by Application USD Billion (2022-2027)
  • Table 314. Australia Pertussis Vaccines, by Vaccine Type USD Billion (2022-2027)
  • Table 315. Australia Pertussis Vaccines, by End User USD Billion (2022-2027)
  • Table 316. Rest of Asia-Pacific Pertussis Vaccines, by Type USD Billion (2022-2027)
  • Table 317. Rest of Asia-Pacific Pertussis Vaccines, by Application USD Billion (2022-2027)
  • Table 318. Rest of Asia-Pacific Pertussis Vaccines, by Vaccine Type USD Billion (2022-2027)
  • Table 319. Rest of Asia-Pacific Pertussis Vaccines, by End User USD Billion (2022-2027)
  • Table 320. Europe Pertussis Vaccines, by Country USD Billion (2022-2027)
  • Table 321. Europe Pertussis Vaccines, by Type USD Billion (2022-2027)
  • Table 322. Europe Pertussis Vaccines, by Application USD Billion (2022-2027)
  • Table 323. Europe Pertussis Vaccines, by Vaccine Type USD Billion (2022-2027)
  • Table 324. Europe Pertussis Vaccines, by End User USD Billion (2022-2027)
  • Table 325. Germany Pertussis Vaccines, by Type USD Billion (2022-2027)
  • Table 326. Germany Pertussis Vaccines, by Application USD Billion (2022-2027)
  • Table 327. Germany Pertussis Vaccines, by Vaccine Type USD Billion (2022-2027)
  • Table 328. Germany Pertussis Vaccines, by End User USD Billion (2022-2027)
  • Table 329. France Pertussis Vaccines, by Type USD Billion (2022-2027)
  • Table 330. France Pertussis Vaccines, by Application USD Billion (2022-2027)
  • Table 331. France Pertussis Vaccines, by Vaccine Type USD Billion (2022-2027)
  • Table 332. France Pertussis Vaccines, by End User USD Billion (2022-2027)
  • Table 333. Italy Pertussis Vaccines, by Type USD Billion (2022-2027)
  • Table 334. Italy Pertussis Vaccines, by Application USD Billion (2022-2027)
  • Table 335. Italy Pertussis Vaccines, by Vaccine Type USD Billion (2022-2027)
  • Table 336. Italy Pertussis Vaccines, by End User USD Billion (2022-2027)
  • Table 337. United Kingdom Pertussis Vaccines, by Type USD Billion (2022-2027)
  • Table 338. United Kingdom Pertussis Vaccines, by Application USD Billion (2022-2027)
  • Table 339. United Kingdom Pertussis Vaccines, by Vaccine Type USD Billion (2022-2027)
  • Table 340. United Kingdom Pertussis Vaccines, by End User USD Billion (2022-2027)
  • Table 341. Netherlands Pertussis Vaccines, by Type USD Billion (2022-2027)
  • Table 342. Netherlands Pertussis Vaccines, by Application USD Billion (2022-2027)
  • Table 343. Netherlands Pertussis Vaccines, by Vaccine Type USD Billion (2022-2027)
  • Table 344. Netherlands Pertussis Vaccines, by End User USD Billion (2022-2027)
  • Table 345. Rest of Europe Pertussis Vaccines, by Type USD Billion (2022-2027)
  • Table 346. Rest of Europe Pertussis Vaccines, by Application USD Billion (2022-2027)
  • Table 347. Rest of Europe Pertussis Vaccines, by Vaccine Type USD Billion (2022-2027)
  • Table 348. Rest of Europe Pertussis Vaccines, by End User USD Billion (2022-2027)
  • Table 349. MEA Pertussis Vaccines, by Country USD Billion (2022-2027)
  • Table 350. MEA Pertussis Vaccines, by Type USD Billion (2022-2027)
  • Table 351. MEA Pertussis Vaccines, by Application USD Billion (2022-2027)
  • Table 352. MEA Pertussis Vaccines, by Vaccine Type USD Billion (2022-2027)
  • Table 353. MEA Pertussis Vaccines, by End User USD Billion (2022-2027)
  • Table 354. Middle East Pertussis Vaccines, by Type USD Billion (2022-2027)
  • Table 355. Middle East Pertussis Vaccines, by Application USD Billion (2022-2027)
  • Table 356. Middle East Pertussis Vaccines, by Vaccine Type USD Billion (2022-2027)
  • Table 357. Middle East Pertussis Vaccines, by End User USD Billion (2022-2027)
  • Table 358. Africa Pertussis Vaccines, by Type USD Billion (2022-2027)
  • Table 359. Africa Pertussis Vaccines, by Application USD Billion (2022-2027)
  • Table 360. Africa Pertussis Vaccines, by Vaccine Type USD Billion (2022-2027)
  • Table 361. Africa Pertussis Vaccines, by End User USD Billion (2022-2027)
  • Table 362. North America Pertussis Vaccines, by Country USD Billion (2022-2027)
  • Table 363. North America Pertussis Vaccines, by Type USD Billion (2022-2027)
  • Table 364. North America Pertussis Vaccines, by Application USD Billion (2022-2027)
  • Table 365. North America Pertussis Vaccines, by Vaccine Type USD Billion (2022-2027)
  • Table 366. North America Pertussis Vaccines, by End User USD Billion (2022-2027)
  • Table 367. United States Pertussis Vaccines, by Type USD Billion (2022-2027)
  • Table 368. United States Pertussis Vaccines, by Application USD Billion (2022-2027)
  • Table 369. United States Pertussis Vaccines, by Vaccine Type USD Billion (2022-2027)
  • Table 370. United States Pertussis Vaccines, by End User USD Billion (2022-2027)
  • Table 371. Canada Pertussis Vaccines, by Type USD Billion (2022-2027)
  • Table 372. Canada Pertussis Vaccines, by Application USD Billion (2022-2027)
  • Table 373. Canada Pertussis Vaccines, by Vaccine Type USD Billion (2022-2027)
  • Table 374. Canada Pertussis Vaccines, by End User USD Billion (2022-2027)
  • Table 375. Mexico Pertussis Vaccines, by Type USD Billion (2022-2027)
  • Table 376. Mexico Pertussis Vaccines, by Application USD Billion (2022-2027)
  • Table 377. Mexico Pertussis Vaccines, by Vaccine Type USD Billion (2022-2027)
  • Table 378. Mexico Pertussis Vaccines, by End User USD Billion (2022-2027)
  • Table 379. Pertussis Vaccines Sales: by Type(K Units)
  • Table 380. Pertussis Vaccines Sales Whole-Cell Vaccines , by Region K Units (2022-2027)
  • Table 381. Pertussis Vaccines Sales A-Cellular Vaccines , by Region K Units (2022-2027)
  • Table 382. Pertussis Vaccines Sales: by Application(K Units)
  • Table 383. Pertussis Vaccines Sales Pediatrics , by Region K Units (2022-2027)
  • Table 384. Pertussis Vaccines Sales Adults , by Region K Units (2022-2027)
  • Table 385. Pertussis Vaccines Sales: by Vaccine Type(K Units)
  • Table 386. Pertussis Vaccines Sales DTaP [Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quaracel] , by Region K Units (2022-2027)
  • Table 387. Pertussis Vaccines Sales Tdap [Boostrix and Adacel] , by Region K Units (2022-2027)
  • Table 388. Pertussis Vaccines Sales: by End User(K Units)
  • Table 389. Pertussis Vaccines Sales Hospitals , by Region K Units (2022-2027)
  • Table 390. Pertussis Vaccines Sales Clinics , by Region K Units (2022-2027)
  • Table 391. Pertussis Vaccines Sales Vaccine Centers , by Region K Units (2022-2027)
  • Table 392. South America Pertussis Vaccines Sales, by Country K Units (2022-2027)
  • Table 393. South America Pertussis Vaccines Sales, by Type K Units (2022-2027)
  • Table 394. South America Pertussis Vaccines Sales, by Application K Units (2022-2027)
  • Table 395. South America Pertussis Vaccines Sales, by Vaccine Type K Units (2022-2027)
  • Table 396. South America Pertussis Vaccines Sales, by End User K Units (2022-2027)
  • Table 397. Brazil Pertussis Vaccines Sales, by Type K Units (2022-2027)
  • Table 398. Brazil Pertussis Vaccines Sales, by Application K Units (2022-2027)
  • Table 399. Brazil Pertussis Vaccines Sales, by Vaccine Type K Units (2022-2027)
  • Table 400. Brazil Pertussis Vaccines Sales, by End User K Units (2022-2027)
  • Table 401. Argentina Pertussis Vaccines Sales, by Type K Units (2022-2027)
  • Table 402. Argentina Pertussis Vaccines Sales, by Application K Units (2022-2027)
  • Table 403. Argentina Pertussis Vaccines Sales, by Vaccine Type K Units (2022-2027)
  • Table 404. Argentina Pertussis Vaccines Sales, by End User K Units (2022-2027)
  • Table 405. Rest of South America Pertussis Vaccines Sales, by Type K Units (2022-2027)
  • Table 406. Rest of South America Pertussis Vaccines Sales, by Application K Units (2022-2027)
  • Table 407. Rest of South America Pertussis Vaccines Sales, by Vaccine Type K Units (2022-2027)
  • Table 408. Rest of South America Pertussis Vaccines Sales, by End User K Units (2022-2027)
  • Table 409. Asia Pacific Pertussis Vaccines Sales, by Country K Units (2022-2027)
  • Table 410. Asia Pacific Pertussis Vaccines Sales, by Type K Units (2022-2027)
  • Table 411. Asia Pacific Pertussis Vaccines Sales, by Application K Units (2022-2027)
  • Table 412. Asia Pacific Pertussis Vaccines Sales, by Vaccine Type K Units (2022-2027)
  • Table 413. Asia Pacific Pertussis Vaccines Sales, by End User K Units (2022-2027)
  • Table 414. China Pertussis Vaccines Sales, by Type K Units (2022-2027)
  • Table 415. China Pertussis Vaccines Sales, by Application K Units (2022-2027)
  • Table 416. China Pertussis Vaccines Sales, by Vaccine Type K Units (2022-2027)
  • Table 417. China Pertussis Vaccines Sales, by End User K Units (2022-2027)
  • Table 418. Japan Pertussis Vaccines Sales, by Type K Units (2022-2027)
  • Table 419. Japan Pertussis Vaccines Sales, by Application K Units (2022-2027)
  • Table 420. Japan Pertussis Vaccines Sales, by Vaccine Type K Units (2022-2027)
  • Table 421. Japan Pertussis Vaccines Sales, by End User K Units (2022-2027)
  • Table 422. India Pertussis Vaccines Sales, by Type K Units (2022-2027)
  • Table 423. India Pertussis Vaccines Sales, by Application K Units (2022-2027)
  • Table 424. India Pertussis Vaccines Sales, by Vaccine Type K Units (2022-2027)
  • Table 425. India Pertussis Vaccines Sales, by End User K Units (2022-2027)
  • Table 426. South Korea Pertussis Vaccines Sales, by Type K Units (2022-2027)
  • Table 427. South Korea Pertussis Vaccines Sales, by Application K Units (2022-2027)
  • Table 428. South Korea Pertussis Vaccines Sales, by Vaccine Type K Units (2022-2027)
  • Table 429. South Korea Pertussis Vaccines Sales, by End User K Units (2022-2027)
  • Table 430. Taiwan Pertussis Vaccines Sales, by Type K Units (2022-2027)
  • Table 431. Taiwan Pertussis Vaccines Sales, by Application K Units (2022-2027)
  • Table 432. Taiwan Pertussis Vaccines Sales, by Vaccine Type K Units (2022-2027)
  • Table 433. Taiwan Pertussis Vaccines Sales, by End User K Units (2022-2027)
  • Table 434. Australia Pertussis Vaccines Sales, by Type K Units (2022-2027)
  • Table 435. Australia Pertussis Vaccines Sales, by Application K Units (2022-2027)
  • Table 436. Australia Pertussis Vaccines Sales, by Vaccine Type K Units (2022-2027)
  • Table 437. Australia Pertussis Vaccines Sales, by End User K Units (2022-2027)
  • Table 438. Rest of Asia-Pacific Pertussis Vaccines Sales, by Type K Units (2022-2027)
  • Table 439. Rest of Asia-Pacific Pertussis Vaccines Sales, by Application K Units (2022-2027)
  • Table 440. Rest of Asia-Pacific Pertussis Vaccines Sales, by Vaccine Type K Units (2022-2027)
  • Table 441. Rest of Asia-Pacific Pertussis Vaccines Sales, by End User K Units (2022-2027)
  • Table 442. Europe Pertussis Vaccines Sales, by Country K Units (2022-2027)
  • Table 443. Europe Pertussis Vaccines Sales, by Type K Units (2022-2027)
  • Table 444. Europe Pertussis Vaccines Sales, by Application K Units (2022-2027)
  • Table 445. Europe Pertussis Vaccines Sales, by Vaccine Type K Units (2022-2027)
  • Table 446. Europe Pertussis Vaccines Sales, by End User K Units (2022-2027)
  • Table 447. Germany Pertussis Vaccines Sales, by Type K Units (2022-2027)
  • Table 448. Germany Pertussis Vaccines Sales, by Application K Units (2022-2027)
  • Table 449. Germany Pertussis Vaccines Sales, by Vaccine Type K Units (2022-2027)
  • Table 450. Germany Pertussis Vaccines Sales, by End User K Units (2022-2027)
  • Table 451. France Pertussis Vaccines Sales, by Type K Units (2022-2027)
  • Table 452. France Pertussis Vaccines Sales, by Application K Units (2022-2027)
  • Table 453. France Pertussis Vaccines Sales, by Vaccine Type K Units (2022-2027)
  • Table 454. France Pertussis Vaccines Sales, by End User K Units (2022-2027)
  • Table 455. Italy Pertussis Vaccines Sales, by Type K Units (2022-2027)
  • Table 456. Italy Pertussis Vaccines Sales, by Application K Units (2022-2027)
  • Table 457. Italy Pertussis Vaccines Sales, by Vaccine Type K Units (2022-2027)
  • Table 458. Italy Pertussis Vaccines Sales, by End User K Units (2022-2027)
  • Table 459. United Kingdom Pertussis Vaccines Sales, by Type K Units (2022-2027)
  • Table 460. United Kingdom Pertussis Vaccines Sales, by Application K Units (2022-2027)
  • Table 461. United Kingdom Pertussis Vaccines Sales, by Vaccine Type K Units (2022-2027)
  • Table 462. United Kingdom Pertussis Vaccines Sales, by End User K Units (2022-2027)
  • Table 463. Netherlands Pertussis Vaccines Sales, by Type K Units (2022-2027)
  • Table 464. Netherlands Pertussis Vaccines Sales, by Application K Units (2022-2027)
  • Table 465. Netherlands Pertussis Vaccines Sales, by Vaccine Type K Units (2022-2027)
  • Table 466. Netherlands Pertussis Vaccines Sales, by End User K Units (2022-2027)
  • Table 467. Rest of Europe Pertussis Vaccines Sales, by Type K Units (2022-2027)
  • Table 468. Rest of Europe Pertussis Vaccines Sales, by Application K Units (2022-2027)
  • Table 469. Rest of Europe Pertussis Vaccines Sales, by Vaccine Type K Units (2022-2027)
  • Table 470. Rest of Europe Pertussis Vaccines Sales, by End User K Units (2022-2027)
  • Table 471. MEA Pertussis Vaccines Sales, by Country K Units (2022-2027)
  • Table 472. MEA Pertussis Vaccines Sales, by Type K Units (2022-2027)
  • Table 473. MEA Pertussis Vaccines Sales, by Application K Units (2022-2027)
  • Table 474. MEA Pertussis Vaccines Sales, by Vaccine Type K Units (2022-2027)
  • Table 475. MEA Pertussis Vaccines Sales, by End User K Units (2022-2027)
  • Table 476. Middle East Pertussis Vaccines Sales, by Type K Units (2022-2027)
  • Table 477. Middle East Pertussis Vaccines Sales, by Application K Units (2022-2027)
  • Table 478. Middle East Pertussis Vaccines Sales, by Vaccine Type K Units (2022-2027)
  • Table 479. Middle East Pertussis Vaccines Sales, by End User K Units (2022-2027)
  • Table 480. Africa Pertussis Vaccines Sales, by Type K Units (2022-2027)
  • Table 481. Africa Pertussis Vaccines Sales, by Application K Units (2022-2027)
  • Table 482. Africa Pertussis Vaccines Sales, by Vaccine Type K Units (2022-2027)
  • Table 483. Africa Pertussis Vaccines Sales, by End User K Units (2022-2027)
  • Table 484. North America Pertussis Vaccines Sales, by Country K Units (2022-2027)
  • Table 485. North America Pertussis Vaccines Sales, by Type K Units (2022-2027)
  • Table 486. North America Pertussis Vaccines Sales, by Application K Units (2022-2027)
  • Table 487. North America Pertussis Vaccines Sales, by Vaccine Type K Units (2022-2027)
  • Table 488. North America Pertussis Vaccines Sales, by End User K Units (2022-2027)
  • Table 489. United States Pertussis Vaccines Sales, by Type K Units (2022-2027)
  • Table 490. United States Pertussis Vaccines Sales, by Application K Units (2022-2027)
  • Table 491. United States Pertussis Vaccines Sales, by Vaccine Type K Units (2022-2027)
  • Table 492. United States Pertussis Vaccines Sales, by End User K Units (2022-2027)
  • Table 493. Canada Pertussis Vaccines Sales, by Type K Units (2022-2027)
  • Table 494. Canada Pertussis Vaccines Sales, by Application K Units (2022-2027)
  • Table 495. Canada Pertussis Vaccines Sales, by Vaccine Type K Units (2022-2027)
  • Table 496. Canada Pertussis Vaccines Sales, by End User K Units (2022-2027)
  • Table 497. Mexico Pertussis Vaccines Sales, by Type K Units (2022-2027)
  • Table 498. Mexico Pertussis Vaccines Sales, by Application K Units (2022-2027)
  • Table 499. Mexico Pertussis Vaccines Sales, by Vaccine Type K Units (2022-2027)
  • Table 500. Mexico Pertussis Vaccines Sales, by End User K Units (2022-2027)
  • Table 501. Pertussis Vaccines: by Type(USD/Units)
  • Table 502. Research Programs/Design for This Report
  • Table 503. Key Data Information from Secondary Sources
  • Table 504. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pertussis Vaccines: by Type USD Billion (2016-2021)
  • Figure 5. Global Pertussis Vaccines: by Application USD Billion (2016-2021)
  • Figure 6. Global Pertussis Vaccines: by Vaccine Type USD Billion (2016-2021)
  • Figure 7. Global Pertussis Vaccines: by End User USD Billion (2016-2021)
  • Figure 8. South America Pertussis Vaccines Share (%), by Country
  • Figure 9. Asia Pacific Pertussis Vaccines Share (%), by Country
  • Figure 10. Europe Pertussis Vaccines Share (%), by Country
  • Figure 11. MEA Pertussis Vaccines Share (%), by Country
  • Figure 12. North America Pertussis Vaccines Share (%), by Country
  • Figure 13. Global Pertussis Vaccines: by Type K Units (2016-2021)
  • Figure 14. Global Pertussis Vaccines: by Application K Units (2016-2021)
  • Figure 15. Global Pertussis Vaccines: by Vaccine Type K Units (2016-2021)
  • Figure 16. Global Pertussis Vaccines: by End User K Units (2016-2021)
  • Figure 17. South America Pertussis Vaccines Share (%), by Country
  • Figure 18. Asia Pacific Pertussis Vaccines Share (%), by Country
  • Figure 19. Europe Pertussis Vaccines Share (%), by Country
  • Figure 20. MEA Pertussis Vaccines Share (%), by Country
  • Figure 21. North America Pertussis Vaccines Share (%), by Country
  • Figure 22. Global Pertussis Vaccines: by Type USD/Units (2016-2021)
  • Figure 23. Global Pertussis Vaccines share by Players 2021 (%)
  • Figure 24. Global Pertussis Vaccines share by Players (Top 3) 2021(%)
  • Figure 25. Global Pertussis Vaccines share by Players (Top 5) 2021(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Sanofi Pasteur (France) Revenue, Net Income and Gross profit
  • Figure 28. Sanofi Pasteur (France) Revenue: by Geography 2021
  • Figure 29. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2021
  • Figure 31. Protein Sciences Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 32. Protein Sciences Corporation (United States) Revenue: by Geography 2021
  • Figure 33. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. Novartis AG (Switzerland) Revenue: by Geography 2021
  • Figure 35. Seqirus (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 36. Seqirus (United Kingdom) Revenue: by Geography 2021
  • Figure 37. Merck Sharp & Dohme Corp. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Merck Sharp & Dohme Corp. (United States) Revenue: by Geography 2021
  • Figure 39. Astellas Pharma US, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Astellas Pharma US, Inc. (United States) Revenue: by Geography 2021
  • Figure 41. Mitsubishi Tanabe Pharma (Japan) Revenue, Net Income and Gross profit
  • Figure 42. Mitsubishi Tanabe Pharma (Japan) Revenue: by Geography 2021
  • Figure 43. Wuhan Institute of Biological Products (China) Revenue, Net Income and Gross profit
  • Figure 44. Wuhan Institute of Biological Products (China) Revenue: by Geography 2021
  • Figure 45. Walvax Biotechnology Co (China) Revenue, Net Income and Gross profit
  • Figure 46. Walvax Biotechnology Co (China) Revenue: by Geography 2021
  • Figure 47. Beijing Minhai Biotechnology Co (China) Revenue, Net Income and Gross profit
  • Figure 48. Beijing Minhai Biotechnology Co (China) Revenue: by Geography 2021
  • Figure 49. Global Pertussis Vaccines: by Type USD Billion (2022-2027)
  • Figure 50. Global Pertussis Vaccines: by Application USD Billion (2022-2027)
  • Figure 51. Global Pertussis Vaccines: by Vaccine Type USD Billion (2022-2027)
  • Figure 52. Global Pertussis Vaccines: by End User USD Billion (2022-2027)
  • Figure 53. South America Pertussis Vaccines Share (%), by Country
  • Figure 54. Asia Pacific Pertussis Vaccines Share (%), by Country
  • Figure 55. Europe Pertussis Vaccines Share (%), by Country
  • Figure 56. MEA Pertussis Vaccines Share (%), by Country
  • Figure 57. North America Pertussis Vaccines Share (%), by Country
  • Figure 58. Global Pertussis Vaccines: by Type K Units (2022-2027)
  • Figure 59. Global Pertussis Vaccines: by Application K Units (2022-2027)
  • Figure 60. Global Pertussis Vaccines: by Vaccine Type K Units (2022-2027)
  • Figure 61. Global Pertussis Vaccines: by End User K Units (2022-2027)
  • Figure 62. South America Pertussis Vaccines Share (%), by Country
  • Figure 63. Asia Pacific Pertussis Vaccines Share (%), by Country
  • Figure 64. Europe Pertussis Vaccines Share (%), by Country
  • Figure 65. MEA Pertussis Vaccines Share (%), by Country
  • Figure 66. North America Pertussis Vaccines Share (%), by Country
  • Figure 67. Global Pertussis Vaccines: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Sanofi Pasteur (France)
  • GlaxoSmithKline (United Kingdom)
  • Protein Sciences Corporation (United States)
  • Novartis AG (Switzerland)
  • Seqirus (United Kingdom)
  • Merck Sharp & Dohme Corp. (United States)
  • Astellas Pharma US, Inc. (United States)
  • Mitsubishi Tanabe Pharma (Japan)
  • Wuhan Institute of Biological Products (China)
  • Walvax Biotechnology Co (China)
  • Beijing Minhai Biotechnology Co (China)
Select User Access Type

Key Highlights of Report


Jul 2022 159 Pages 75 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Pertussis Vaccines Market Quantitative research analysis
Global Pertussis Vaccines Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The prominent players of Global Pertussis Vaccines market are Sanofi Pasteur (France), GlaxoSmithKline (United Kingdom), Protein Sciences Corporation (United States), Novartis AG (Switzerland), Seqirus (United Kingdom), Merck Sharp & Dohme Corp. (United States), Astellas Pharma US, Inc. (United States), Mitsubishi Tanabe Pharma (Japan), Wuhan Institute of Biological Products (China), Walvax Biotechnology Co (China) and Beijing Minhai Biotechnology Co (China).
In this highly competitive & fast evolving Pertussis Vaccines industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.
Pediatrics and Adults are the potential customers of Pertussis Vaccines industry.
The Global Pertussis Vaccines market is expected to see a growth of 1.6% during projected year 2021 to 2027.

Know More About Global Pertussis Vaccines Market Report?

Have a Query? Click Here

Other Related Reports

Body Plethysmography Comprehensive Study by Type (Whole Body, Part of Body), Application (Adults, Kids), End-User (Hospitals, Fitness centers, Academic & Research centres, Others) Players and Region ...
$ 3500
Bispecific Antibodies Comprehensive Study by Type (Trifunctional Antibodies, Chemically Linked Fabs, Bispecific T Cell Engagers (BiTEs).), Application (Hospitals, Diagnostic Centers, Academic and Res...
$ 3750
Automated Gram Stainer Comprehensive Study by Application (In-house Research, Commercial Research, Clinical Diagnosis), Slide Capacity (Upto 12 Slide, 13 - 30 slides, 31 -50 slides, Above 50 slides),...
$ 3650
Cellular Therapy in Oncology Comprehensive Study by Type (Consumables, Equipment (Cell Processing Equipment, Single-use Equipment), Systems & Software), Technology (Bioreactor, Cell Immortalization T...
$ 3750
Tissue Engineering and Organ Regeneration Comprehensive Study by Type (Tissue-engineered Products, Cell Therapies (Autologous Therapies, Allogenic Therapies), Gene Therapies, Progenitor & Stem Cell T...
$ 3650
Somatic Genetic Testing Comprehensive Study by Type (Product (Kits and Assays, Instruments, and Software), Services), Application (Solid Tumors (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lun...
$ 3750